Curacle's Diabetic Macular Edema Treatment 'CU06' Receives US FDA Approval for Phase 2a Clinical Trial

[Asia Economy Reporter Lee Gwan-joo] Curacle announced on the 26th that it has obtained approval from the U.S. Food and Drug Administration (FDA) for the Phase 2a clinical trial of the oral treatment for diabetic macular edema, 'CU06.'

Curacle plans to attend the investigator meeting scheduled during the American Academy of Ophthalmology (AAO) conference held in Chicago, USA, in early next month, and will begin full-scale patient recruitment and dosing.

A Curacle official stated, "There is high interest from researchers in this Phase 2 trial of CU06, and since the oral administration method is preferred by patients, it is expected to proceed quickly," adding, "We also expect the clinical studies to expand indications for many of Curacle's pipelines to accelerate."